Skip to main content

Advertisement

SpringerLink
Log in

Drugging cancer genomes

  • Comment
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

A recent landmark analysis compared genome-wide mutations and associated 'omics' features for 3,281 tumours across 12 human cancer types. There is a clear need for objective target assessment and prioritization by the drug discovery community to make the best use of such vast amounts of data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).

    Article  CAS  Google Scholar 

  2. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).

    Article  CAS  Google Scholar 

  3. Futreal, P. A. et al. A census of human cancer genes. Nature Rev. Cancer 4, 177–183 (2004).

    Article  CAS  Google Scholar 

  4. Patel, M. N. et al. Objective assessment of cancer genes for drug discovery. Nature Rev. Drug Discov. 12, 35–50 (2013).

    Article  CAS  Google Scholar 

  5. Halling-Brown, M. D. et al. canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Res. 40, D947–D956 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cancer Therapeutics, Paul Workman and Bissan Al-Lazikani are at the Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.,

    Paul Workman & Bissan Al-Lazikani

Authors
  1. Paul Workman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bissan Al-Lazikani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Paul Workman or Bissan Al-Lazikani.

Ethics declarations

Competing interests

The authors work at The Institute of Cancer Research, London, UK, which has a commercial interest in the discovery and development of anticancer drugs.

Supplementary information

Supplementary information S1 (box)

Objective analysis of cancer genes (PDF 2031 kb)

Related links

Related links

FURTHER INFORMATION

The Cancer Genome Atlas

International Cancer Genome Consortium

Focus on TCGA Pan-Cancer Analysis

canSAR knowledgebase

Rights and permissions

Reprints and permissions

About this article

Cite this article

Workman, P., Al-Lazikani, B. Drugging cancer genomes. Nat Rev Drug Discov 12, 889–890 (2013). https://doi.org/10.1038/nrd4184

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4184

  • Springer Nature Limited

This article is cited by

Search

Navigation